• Divya Saxena Guru Nanak Institute of Research and Development, Guru Nanak Khalsa College, Opp. Don Bosco School, Nathalal Parekh Marg, Matunga-east, Mumbai – 400 019, Maharashtra, India
  • Shailesh Damale
  • Ajit Datar


Keywords, Etodolac, metabolites, hepatic cell lines, chicken liver tissue, LC, LC-MSMS


Objective: The main objective of this study was to investigate the in vitro metabolic profile of etodolac (ETD) using normal human hepatic cell lines and chicken liver tissue, and to characterize the metabolites obtained using Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS).

Methods: In the present study, the metabolic profile of ETD, a well-known non-steroidal anti-inflammatory drug (NSAID), was investigated in normal human hepatic cell lines and chicken liver tissue employing LC-MS/MS technique. The structural details on ETD metabolites were acquired using triple quadrupole mass spectrometer (LCMS-8040, Shimadzu). The metabolites were produced by incubation of ETD with the human hepatic cell lines and chicken liver tissue, at 37 °C for 24 h. The incubated extracts were analyzed with LC-MS/MS and their production spectra were acquired, interpreted and tentative structures were proposed.

Results: Six phase I and phase II metabolites were successfully detected in the proposed study. The metabolic changes observed included-oxidation, N-acetylation, hydrogenation, decarboxylation, methylation and glucuronidation of dehydrogenated ETD. The tentative structures of the metabolites were postulated based on the chemical reactions predicted and the LC-MS/MS data obtained.

Conclusion: The in vitro metabolites of ETD were successfully investigated and characterized in human hepatic cell lines and chicken liver tissue. Also, both the models were found to be equally effective for carrying out the in vitro metabolic study of ETD.

Keywords: Etodolac, Metabolites, Hepatic cell lines, Chicken liver tissue, LC, LC-MS/MS


Download data is not yet available.


Patel A, Shah B. RP-HPLC method development and validation using the factorial design for simultaneous estimation of thi°Colchicoside and etodolac with forced degradation studies. J Pharma Sci Biosci Res 2014;4:374-82.

Pandey R, Patil PO, Bari SB, Dhumal DM. Simultaneous estimation of etodolac and thi°Colchicoside in bulk and in tablet formulation by UV spectrophotometry. Chem Ind Chem Eng Q 2014;20:9-17.

Dirk BS, Gottfried B. Isolation of an unknown metabolite of the non-steroidal anti-inflammatory drug Etodolac and its identification as 5-hydroxy Etodolac. J Pharm Biomed Anal 2001;25:977-84.

Devarakonda RK, Ulrich K. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994;26:144-60.

Schonborn LJ. The role of the liver in drug metabolism. Anaesthesia Tutorail Week 2010;179:1-6.

Prakash C, Shaffer CL, Nedderman A. Analytical strategies for identifying drug metabolites. Mass Spectrom Rev 2007;26:340-69.

Brandon EF, Raap CD, Meijeram I, Benjnen JH, Schellens JH. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 2003;189:233-46.

Fasinu P, Bouic PJ, Rosenkranz B. Liver based in vitro technologies for drug biotransformation studies-a review. Curr Drug Metab 2012;13:215-24.

Becker SU, Blaschke G. Evaluation of the stereoselective metabolism of the chiral analgesic drug Etodolac by high-performance liquid chromatography. J Chromatogr 1993;621:199-207.

Jamali F, Mehvar R, Lemko C, Eradiri O. Application of a stereospecific high-performance liquid chromatography assay to a pharmacokinetic study of Etodolac enantiomers in humans. J Pharm Sci 1988;77:693-6.

Wright MR, Jamali F. Limited extent of stere°Chemical conversion of chiral non-steroidal anti-inflammatory drugs induced by derivatization methods employing ethyl chloroformate. J Chromatogr 1993;616:59-65.

Turcant A, Premel-Cabic A, Cailleux A, Allian P. Toxicological screening of drugs by microbore high-performance liquid chromatography with photodiode-array detection and ultraviolet spectral library searches. Clin Chem 1991;37:1210-5.

Lapicque F, Netter P, Bannwarth B, Trechot P, Gillet P, Lambert H, et al. Identification and simultaneous determination of non-steroidal anti-inflammatory drugs using high-performance liquid chromatography. J Chromatogr Biomed Appl 1989;496:301-20.

Pirkle WH, Murray PG. The separation of the enantiomers of a variety of non-steroidal anti-inflammatory drugs (NSAIDs) as their anilide derivatives using a chiral stationary phase. J Liq Chromatogr 1990;13:2123-34.

Singh NN, Jamali F, Pasutto AS, Coutts RT, Russel AS. Stereoselective gas chromatographic analysis of Etodolac enantiomers in human plasma and urine. J Chromatogr 1988;382:331-7.

Schmutz A, Thomann W. Assessment of the impact of physic°Chemical drug properties on monitoring drug levels by micellar electrokinetic capillary chromatography with direct serum injection. Electrophoresis 1994;15:1295-303.

Mayer S, Schurg V. Enantiomeric separation by electro chromatography in open tubular columns coated with Chiral-DEX. J Liq Chromatogr 1993;16:915-31.

Giachetti C, Assandri A, Zanolo G, Brembila E. Gas chromatography-mass spectrometry determination of Etodolac in human plasma following single epicutaneous administration. J Chromatogr Biomed Appl 1994;8:180-3.

Dirk BS, Chankvetadze B, Blaschke G, Claudia D, Salvatore F. Separation and identification of etodolac and its urinary phase I metabolites using capillary electro chromatography and on-line capillary electro chromatography–electrospray ionization mass spectrometry coupling. J Chromatogr A 2000;887:393-407.

Mohammed R, Abyazani K, Esaw B. Etodolac in equine urine and serum: Determination by high-performance liquid chromatography with ultraviolet detection, confirmation, and metabolite identification by atmospheric pressure ionization mass spectrometry. J Anal Toxicol 1999;23:200-9.

Ferdinandi ES, Sehgal SN, Demerson CA, Dubuc J, Zilbert J, Dvornik D, et al. Disposition and biotransformation of 14C-etodolac in man. Xenobiotica 1986;16:153-66.

Berendes U, Blaschke G. Simultaneous determination of the phase II metabolites of the non-steroidal anti-inflammatory drug Etodolac in human urine. Enantiomer 1996;1:415-22.

Ferdinandi ES, C°Chran D, Gedamke R. Identification of the Eodolac metabolite, 4-ureidoetodolac, in mouse, rat, dog, and man. Drug Metab Dispos 1987;15:921-4.

Suchanova B, Kostiainen R, Ketola R. Characterization of the in vitro metabolic profile of amlodipine in the rat using liquid chromatography-mass spectrometry. J Pharm Sci 2008;33:91-9.

Suchanova B, Sispera L, Wsol V. Liquid chromatography-tandem mass spectrometry in the chiral study of Amlodipine biotransformation in rat hepat°Cytes. Anal Chim Acta 2006;573:273-83.

Saxena D, Damale S, Datar A, Bhandarkar D, Raju S, Rane S, et al. Characterization of products formed by forced degradation of Etodolac by LC-MS/MS. Presented ASMS 2015;15:1-7.



How to Cite

Saxena, D., S. Damale, and A. Datar. “INVESTIGATION OF IN VITRO METABOLITES OF ETODOLAC IN HUMAN HEPATIC CELL LINE AND CHICKEN LIVER TISSUE USING LC-MS/MS”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 8, no. 7, July 2016, pp. 372-9,



Original Article(s)